AGENDA Subject to change
7:00–8:15 am
Breakfast and Registration*
​
7:30–8:15 am
Industry-Sponsored Event*
Session 1: Defining Cirrhosis: Clinical and Histologic and Radiologic
8:15–8:20 am
Welcome Address
8:20–8:35 am
Clinical Diagnosis of Cirrhosis in Liver Clinic 2026 Including Imaging CT and MRI
8:35–8:50 am
Histologic Diagnosis of Cirrhosis and Role of PATH-AI, HistoIndex: MASH, ALD, Alpha-1 Anti-Trypsin Deficiency, PBC and PSC
8:50–9:05 am
Genetic Risk Score in Cirrhosis and Outcomes
9:05–9:25 am
Serpina 1 and PiZZ and MZ—Identification, Treatment Landscape- Clinical Trial Consideration, and Endpoints
9:25–9:40 am
Cirrhosis Based Upon: Elastography—Role of VCTE, MRE, cT1, ELF, Fibrospect 2, Pro-C3, ADAPT, Anticipate-MASH
9:40–9:55 am
Panel Discussion
9:55–10:20 am
Coffee Break*
​
Session 2: Cirrhosis Biomarkers: From Research to Trials to Clinical Practice
10:20–10:35 am
Baveno VII Update
10:35–10:45 am
GOLDMINE Study Update and MALO
10:45–11:00 am
VCTE-LSM—as Reasonably Likely Surrogate Endpoint = >= 5Kpa and/or > = 30% Increase
11:00–11:15 am
MRE-LSM—as Reasonably Likely Surrogate Endpoint
11:15–11:30 am
ELF as Reasonably Likely Surrogate Endpoint
11:30–11:40 am
Should You Include Patients With Small Varices in Cirrhosis Trials? Focus on Definition of Varices Needing Treatment as an Outcome
11:40 am–12:00 pm
Panel Discussion
​
12:00–1:00 pm
Lunch*
​
12:15–1:00 pm
Industry-Sponsored Event*
Session 3: New Data and Insights on Cirrhosis, and MALO
1:00–1:10 pm
NIT Diagnosis of MASH Cirrhosis—Delphi Panel
1:10–1:20 pm
Pro-C3 and Cell Free DNA as Biomarker for MASH, Cirrhosis and GLP-1 Response
1:20–1:30 pm
Cell Free DNA and Others Biomarkers for HCC in Cirrhosis
1:30–1:35 pm
Oral Abstract 1
1:35–1:40 pm
Oral Abstract 2: Biomarker Integration in Therapeutic Trials for Cirrhosis
1:40–1:45 pm
Question and Answer
1:45–2:00 pm
Key Concepts in MALO and Definitions of Each Outcome: Ascites, Varices Needing Treatment, HE, MELD 15
​
2:00–2:15 pm
Debate in MASH, MetALD and ALD Cirrhosis Trials: Should Peth Be Used to Rule Out a Certain Population in SLD Trials?
​
2:15–2:30 pm
Regulatory Considerations for the Use of Non-Invasive Biomarkers in MASH Cirrhosis Trials: FDA Perspective
2:30–2:50 pm
Panel Discussion
​
2:50–3:10 pm
Coffee Break*
​
Session 4: AI, Emerging Issues in Other Liver Diseases—HBV, Delta, PBC and PSC
3:10–3:20 pm
Liver Cirrhosis Network: Cohort and RESCU Update
3:20–3:30 pm
Artificial Intelligence Applications in Improving Outcomes in Cirrhosis
3:30–3:45 pm
Emerging Therapies for HBV and Delta Hepatitis
3:45–4:00 pm
Trial Design and Outcomes: MAESTRO NASH Cirrhosis, FGF-21 Cirrhosis Trials, Survodutide Cirrhosis Trials
4:00–4:15 pm
Key Considerations in Cirrhosis Trials Design and Outcome Assessment in 2026
​
4:15–4:35 pm
Current and Emerging Therapies for PBC and PSC
​
4:35–4:50 pm
Leveraging Multi-Omic Technologies to Inform Biomarker Discovery in Cirrhosis
4:50–5:00 pm
Final Wrap-Up
​
*Non-accredited Session